Viveve RF treatment is a non ablative RF single treatment for women who have vaginal introital laxity and who are experiencing an associated decrease in physical sensation and sexual satisfaction during intercourse.
Deep low-energy heating
The Viveve Treatment for Vaginal Laxity
The Viveve Treatment is not cosmetic; instead, it works at the cellular level to rebuild and restore collagen and as a result can increase feelings of vaginal tightness and improve sexual satisfaction.
Because the treatment is usually completed in 30 minutes, it generally doesn’t require anesthesia, there is little-to-no downtime – normal activities are resumed following the procedure.
At the beginning of the procedure, the doctor will insert a treatment tip, about the size of your thumb, just inside the vaginal opening. The tip is circumferentially moved around the opening, delivering pulses of radiofrequency energy to the collagen fibers that make up the underlying tissues, while also cooling the vaginal surface.
Vaginal tissue reacts to the energy by stimulating the formation of new collagen fibers restoring the tissue1. This collagen restoration process takes place over time, usually between 30-90 days after the treatment. The changes occur on the cellular level, so there are no outward signs of change to the vaginal tissue.
During vaginal childbirth tissues can overstretch, damaging the collagen and creating a feeling of looseness (laxity), especially around the vaginal opening.
Women who experience laxity may also notice a decreased feeling of sensation and sexual satisfaction during intercourse. These changes can affect a woman’s overall sexual health and quality of life.
Based on available clinical data, the Viveve Treatment is safe and effective. Government regulatory agencies, in countries where the Viveve System is available for sale, have reviewed the safety profile in detail, prior to granting a medical device license or approval to sell or distribute the product.
Side effects seldom occur and are typically mild, temporary, and resolve shortly after treatment. They can include: slight, white vaginal discharge; redness or swelling; slight abdominal discomfort, focal, transient altered sensation and tingling following treatment.
The Viveve Treatment is contraindicated for patients with either an implantable pacemaker or an AICD (Automatic Implantable Cardioverter/Defibrillator) or any other implantable device as they may be adversely affected by radiofrequency (RF) fields or current.